

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

The following full text is a publisher's version.

For additional information about this publication click this link.

<http://hdl.handle.net/2066/50136>

Please be advised that this information was generated on 2022-08-23 and may be subject to change.

Species- and Strain-Specific Control of a Complex, Flexible Regulon by *Bordetella* BvgAS

C. A. Cummings, H. J. Bootsma, D. A. Relman and J. F.
Miller

J. Bacteriol. 2006, 188(5):1775. DOI:
10.1128/JB.188.5.1775-1785.2006.

Updated information and services can be found at:
<http://jb.asm.org/content/188/5/1775>

SUPPLEMENTAL MATERIAL

These include:

<http://jb.asm.org/content/suppl/2006/02/21/188.5.1775.DC1.htm>
|

REFERENCES

This article cites 61 articles, 33 of which can be accessed free
at: <http://jb.asm.org/content/188/5/1775#ref-list-1>

CONTENT ALERTS

Receive: RSS Feeds, eTOCs, free email alerts (when new
articles cite this article), [more»](#)

Information about commercial reprint orders: <http://journals.asm.org/site/misc/reprints.xhtml>
To subscribe to to another ASM Journal go to: <http://journals.asm.org/site/subscriptions/>

Species- and Strain-Specific Control of a Complex, Flexible Regulon by *Bordetella* BvgAS†

C. A. Cummings,^{1,2,‡*} H. J. Bootsma,^{3,‡§} D. A. Relman,^{1,2,4} and J. F. Miller^{3,5}

Departments of Microbiology and Immunology¹ and of Medicine,⁴ Stanford University School of Medicine, Stanford, California 94305; VA Palo Alto Health Care System, Palo Alto, California, 94304²; Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles, California, 90095³; and The Molecular Biology Institute, University of California, Los Angeles, California 90095⁵

Received 30 September 2005/Accepted 12 December 2005

The *Bordetella* master virulence regulatory system, BvgAS, controls a spectrum of gene expression states, including the virulent Bvg⁺ phase, the avirulent Bvg⁻ phase, and at least one Bvg-intermediate (Bvgⁱ) phase. We set out to define the species- and strain-specific features of this regulon based on global gene expression profiling. Rather than functioning as a switch, Bvg controls a remarkable continuum of gene expression states, with hundreds of genes maximally expressed in intermediate phases between the Bvg⁺ and Bvg⁻ poles. Comparative analysis of Bvg regulation in *B. pertussis* and *B. bronchiseptica* revealed a relatively conserved Bvg⁺ phase transcriptional program and identified previously uncharacterized candidate virulence factors. In contrast, control of Bvg⁻ and Bvgⁱ-phase genes diverged substantially between species; regulation of metabolic, transporter, and motility loci indicated an increased capacity in *B. bronchiseptica*, compared to *B. pertussis*, for ex vivo adaptation. Strain comparisons also demonstrated variation in gene expression patterns within species. Among the genes with the greatest variability in patterns of expression, predicted promoter sequences were nearly identical. Our data suggest that the complement of transcriptional regulators is largely responsible for transcriptional diversity. In support of this hypothesis, many putative transcriptional regulators that were Bvg regulated in *B. bronchiseptica* were deleted, inactivated, or unregulated by BvgAS in *B. pertussis*. We propose the concept of a “flexible regulon.” This flexible regulon may prove to be important for pathogen evolution and the diversification of host range specificity.

Bordetellae are gram-negative bacteria that colonize ciliated respiratory epithelial surfaces of a variety of hosts (9). *Bordetella bronchiseptica* causes infections that are typically chronic and often asymptomatic in a broad range of animals (21). Numerous phylogenetic and genomic analyses (see, e.g., references 13, 43, and 59) have indicated this species to be the progenitor of human-restricted agents of acute respiratory disease in humans: *B. pertussis*, which causes whooping cough in children and coughing illness in adolescents and adults (63), and *B. parapertussis*, which confers similar but milder clinical symptoms (22). Despite vaccination, *B. pertussis* remains a major cause of childhood mortality worldwide and is reemerging in some highly vaccinated populations (7, 42, 63). Even though *Bordetella* species are closely related at the nucleotide sequence level, they differ in several respects, such as severity of disease and host range specificity. *B. pertussis* likely evolved from a *B. bronchiseptica*-like ancestor primarily through genome decay (13, 43). Differential gene expression and coding polymorphisms within expressed loci appear to be the primary determinants of species-specific phenotypes (9, 20, 43).

Expression of nearly all known *Bordetella* virulence and colonization factors is controlled by the BvgAS signal transduction system (reviewed in reference 8). In response to a variety of environmental signals, the BvgS transmembrane sensor kinase initiates a multistep phosphorylation cascade that ultimately leads to phosphorylation of the DNA-binding response regulator BvgA. Rather than functioning as an on/off switch, BvgAS controls a spectrum of at least three distinct gene expression states along a regulatory continuum (11). When BvgAS is fully active (Bvg⁺ phase), *B. bronchiseptica* and *B. pertussis* express nearly identical sets of toxins and adhesins, including filamentous hemagglutinin, pertactin, fimbriae, and adenylate cyclase toxin. The transcription of a type III secretion system (TTSS) locus is also Bvg activated in both species, although the synthesis of TTSS proteins appears to be post-transcriptionally blocked specifically in *B. pertussis* (36). A key difference in Bvg-activated gene expression is the pertussis toxin locus (*ptx/ptl*), the coding sequences of which are intact in both species but expressed only in the Bvg⁺ phase of *B. pertussis* (2). Motility loci in *B. bronchiseptica* (1) and virulence-repressed genes (*vrg* genes) in *B. pertussis* (31) are expressed when Bvg is inactive (Bvg⁻ phase). Some genes, such as *bipA*, are maximally expressed between the Bvg⁺ and Bvg⁻ poles (Bvg-intermediate phase [Bvgⁱ]) (15, 53).

While the Bvg⁺ phases of *B. bronchiseptica* and *B. pertussis* appear to be adapted to respiratory tract colonization, the Bvg⁻ phase of *B. bronchiseptica* promotes survival under nutrient-limiting conditions (1, 10, 34, 44). The Bvg⁻ phase of *B. pertussis* is still relatively uncharacterized, and because *B. pertussis* is apparently unable to persist outside the host, this phase

* Corresponding author. Mailing address: VA Palo Alto Health Care System, 154T, Bldg. 101, C4-151, 3801 Miranda Ave., Palo Alto, CA 94304. Phone: (650) 493-5000, ext. 66991. Fax: (650) 852-3291. E-mail: cummings@cmgm.stanford.edu.

† Supplemental material for this article may be found at <http://jb.asm.org/>.

‡ C.A.C. and H.J.B. contributed equally to this work.

§ Present address: Laboratory of Pediatric Infectious Diseases, Radboud University Nijmegen Medical Centre, 6500 HB Nijmegen, The Netherlands.

TABLE 1. Strains used in this study

| Species and strain | Phenotype | Genotype | Parent | Source or reference | Alias | Host ^a |
|--------------------------|------------------|----------------------|----------|---------------------|-------|-------------------|
| <i>B. bronchiseptica</i> | | | | | | |
| RB50 | WT ^b | | | 10 | | Rabbit |
| RB53 | Bvg ⁺ | <i>bvgS-C3</i> | RB50 | 10 | | |
| RB53i | Bvg ⁺ | <i>bvgS-C3, II</i> | RB50 | 11 | | |
| RB54 | Bvg ⁻ | Δ <i>bvgS</i> | RB50 | 10 | | |
| Bbr81 | WT | | | 59 | 732 | Dog |
| Bbr77 | WT | | | 59 | 675 | Human |
| <i>B. pertussis</i> | | | | | | |
| Tohama I | WT | | | 30 | | Human |
| ThSc3 | Bvg ⁺ | <i>bvgS-C3</i> | Tohama I | This study | | |
| ThdS | Bvg ⁻ | Δ <i>bvgS</i> | Tohama I | This study | | |
| GMT-1 | WT | | GG | 35 | | Human |
| GSc3 | Bvg ⁺ | <i>bvgS-C3</i> | GMT-1 | This study | | |
| BPC1.i | Bvg ⁺ | <i>bvgS-C3, II</i> | GMT-1 | 60 | | |
| GMTdS | Bvg ⁻ | Δ <i>bvgS</i> | GMT-1 | This study | | |

^a Host is given only for wild-type strains.

^b WT, wild type.

has been proposed to be an evolutionary remnant (9, 40). The Bvgⁱ phase is thought to be similar in *B. bronchiseptica* and *B. pertussis* (17) and may be involved in biofilm formation (25) and aerosol transmission (11, 60).

Although the signals that influence BvgAS in vivo remain unknown, Bvg-regulated gene expression can be precisely regulated in vitro: BvgS is active during growth at 37°C, but temperatures below 26°C or the presence of millimolar amounts of nicotinic acid (NA) or sulfate anion (modulating signals) render BvgS inactive (37, 41). Furthermore, *bvgS* “phase-locked” mutant alleles can be used to freeze the signaling system in specific positions along the regulatory continuum (9).

Using the complementary approaches of environmental modulation and phase-locked mutants for global expression analysis, we defined the full BvgAS regulons in *B. pertussis* and *B. bronchiseptica*. By comparing the species’ expression profiles, we sought to identify novel virulence determinants and discover the genetic basis of species-specific phenotypes. To understand the pathogenic and physiological adaptations required for survival in the host environment, we explored the dynamic Bvg-regulated transcription patterns upon environmental modulation and examined regulation of transporter repertoires and metabolic pathways. By identifying novel Bvg⁻ and Bvgⁱ phase genes, we sought to elucidate the roles for these phases in the *Bordetella* life cycle. To assess intraspecific gene expression diversity, we examined strain-specific Bvg regulation within *B. bronchiseptica* and *B. pertussis*. Finally, by comparing promoter sequences and Bvg-regulated transcription factors, we identified possible mechanisms of differential gene expression.

MATERIALS AND METHODS

Bacterial strains and growth conditions. Strains used in this study are listed in Table 1. Bvg⁺ and Bvg⁻ phase-locked derivatives of *B. pertussis* were constructed by introducing the respective *bvgS* alleles by allelic exchange as described previously (34). *Bordetella* strains were grown on BG agar (Becton Dickinson, Franklin Lakes, NJ) supplemented with 7.5% or 15% sheep blood for *B. bronchiseptica* and *B. pertussis*, respectively. For RNA isolation, cultures were grown overnight at 37°C in modified Steiner-Scholte medium (SSM) and then reinoculated into prewarmed medium at an optical density at 600 nm of approximately

0.05 to 0.1. Cultures were incubated at 37°C until they reached mid-log phase, at which point they were harvested by centrifugation for 30 seconds. (No samples were taken at an optical density at 600 nm exceeding 1.5, at which point the culture is still growing logarithmically under these conditions.) For steady-state modulation experiments, NA was added to both overnight and log-phase cultures at the concentrations indicated below. For phase shift experiments, cultures were grown to mid-log phase in SSM containing 75 mM magnesium sulfate, pelleted by centrifugation, resuspended in prewarmed magnesium sulfate-free SSM, and incubated at 37°C throughout the course of sampling.

Microarray analysis. Cy5-labeled cDNA was hybridized to spotted DNA microarrays with a Cy3-labeled reference. The reference sample for these experiments was one of two preparations. In some cases a common reference mixture of RNA samples from modulated and unmodulated *B. pertussis* Tohama I and *B. bronchiseptica* RB50 as well as their phase-locked derivatives was labeled with Cy3. In other cases, as described by Talaat et al. (54), we used a Cy3-labeled genomic DNA sample comprised of a 1:1:1 mixture of the three genomes that are represented on the array as described previously (13). All samples in a given experiment (i.e., set of phase-locked strains, NA dose curve, or time course) were processed using the same reference, and data obtained from the two methods were not combined during analysis. Details on nucleic acid isolation, labeling, and microarray construction are given in Methods in the supplemental material.

Background-subtracted Cy5/Cy3 intensity ratios were determined for spots meeting quality control criteria and then averaged across replicates and normalized. For comparison of phase-locked strains, a fold change cutoff of 2.1 was chosen to select Bvg-regulated genes. This threshold was consistent with all but the lowest fold changes of transcripts determined to be significant by significance analysis of microarrays (57) but was more inclusive of known Bvg-regulated genes. For modulation experiments, to be considered Bvg regulated, genes were required to have data from all array hybridizations and a fold change between the maximum and minimum values across the data set exceeding a threshold of 2.4 for *B. bronchiseptica* and 2.0 for *B. pertussis*. The selection of cutoffs was chosen empirically to maximize inclusion of known Bvg-regulated genes while minimizing apparent noise. For comparison of *B. bronchiseptica* strains, genes with at least three measurements per strain and a fold change of at least 2.1 were considered regulated. Data were clustered using the self-organizing tree algorithm (23), after which nodes were reordered manually based on the mean expression profile within each node. Further details are in Methods in the supplemental material.

Gene annotation is as described previously (43), with functional categories according to MultiFun (50). Open reading frame (ORFs) assigned to the “virulence factors” category were reassigned to a functional class reflecting their cellular function (see the tables in the supplemental material). MultiFun categories 7.0.0 (some information, but not classifiable) and 0.0.0 (unknown proteins, no known homologues) were combined into the class “hypothetical ORFs.” Metabolic pathway analysis employed Pathway Tools (29) and automatically generated pathway genome databases from BioCyc (SRI Interna-

tional; [http://biocyc.org/BBRO518/organism-summary?object=BBRO518 and http://biocyc.org/BPER520/organism-summary?object=BPER520]). Further annotation of predicted transporters was obtained from TransportDB (47).

Real-time PCR. SYBR Green real-time reverse transcription-PCR assays were used to determine transcript levels of selected genes. The relative quantitation method ($\Delta\Delta C_T$) (33) was used to evaluate variation between phase-locked strains relative to each gene examined. Further details are in Methods in the supplemental material.

Motif identification. Genes were first grouped into putative operons (see Tables S1 and S2 in the supplemental material). MEME (3) was used to search the upstream sequences of coregulated operons for conserved motifs of between 6 and 20 nucleotides (nt). Motifs discovered by this method are weighted statistical models. To assess whether they were specific to the regulated operons, multiple alignments of motifs were input to HMMer (version 1.8.4; S. R. Eddy, Washington University [http://hmmer.wustl.edu]) in order to construct hidden Markov models that were used to search both coregulated genes and unregulated genes. The scores from searches against unregulated genes were used to set the 98th percentile score for each motif. Motifs with scores exceeding this threshold in the coregulated genes were considered significant. Sequence logo displays were created using SEQLOGO (12). Details are in Methods in the supplemental material.

Accession numbers. Microarray data have been deposited in ArrayExpress as E-MEXP-399, E-TABM-27, E-TABM-28, E-TABM-29, E-TABM-30, and E-TABM-31.

RESULTS

Species-specific regulation by BvgAS. Genes expressed at either end of the Bvg phase spectrum were identified by microarray-based transcriptional profiling of Bvg⁺ and Bvg⁻ phase-locked derivatives of *B. bronchiseptica* RB50 and *B. pertussis* GMT-1 (Table 1). Data and enhanced figures are available in the supplemental material and at <http://asiago.stanford.edu/BvgAS>.

Two hundred eighty-eight genes were classified as Bvg activated and 250 as Bvg repressed (Fig. 1A; see Tables S3 and S4 in the supplemental material). Twenty-nine percent of the Bvg-activated genes were shared by RB50 and GMT-1, but 59% were regulated only in RB50. In contrast, 86% Bvg-repressed genes were so regulated only in RB50. Twenty-nine percent of the genes regulated by BvgAS specifically in RB50 were presumed to be missing from or highly divergent in the GMT-1 genome based upon comparative genome hybridization analysis (Fig. 1A and data not shown). (Such genes were treated as components of the *B. bronchiseptica*-specific regulon. In the tables in the supplemental material, genes that are absent, by comparative sequencing or comparative genome hybridization analysis, are indicated to distinguish them from those in which transcriptional abundance of an intact gene is being differentially regulated.) Microarray data were validated by quantitative real-time PCR assays of 38 RB50 genes and 29 GMT-1 genes. Microarray and reverse transcription-PCR data were highly concordant for RB50 ($r^2 = 0.92$) (Fig. 2) and GMT-1 ($r^2 = 0.80$) (not shown).

The Bvg-activated genes of *B. pertussis* and *B. bronchiseptica* were similarly distributed among functional categories and were enriched for genes predicted to encode proteins involved in folding and ushering and in transport and proteins expressed on the cell surface (see Fig. S1 in the supplemental material). The expected preferential expression of known virulence factors in the Bvg⁺ phase in both species was corroborated (see Table S5 in the supplemental material). Of the fimbrial major subunit genes, *fim2* and *fimA* were Bvg-activated genes in both




FIG. 1. Distribution of differentially expressed genes. The distributions of Bvg-activated and Bvg-repressed genes among *B. bronchiseptica* RB50 and *B. pertussis* GMT-1 (A), three *B. bronchiseptica* strains (B), and two *B. pertussis* strains (C) are shown. Areas within Venn diagrams are drawn approximately to scale, and the number of ORFs in each is indicated. In parentheses are numbers of genes absent from the other genome(s) as determined by genome sequence comparison (RB50 and Tohama I) or comparative genome hybridization (GMT-1).

species, but *fim3*, *fimX*, *fimN*, and BB3424 were Bvg activated only in RB50.

Genes coregulated with bona fide virulence factors may be candidate virulence determinants, particularly if sequence motifs suggest a direct role in pathogenesis. Eight autotransporter genes, including five encoding known virulence factors, were Bvg activated in both species, and two more were Bvg activated in *B. bronchiseptica*. Several iron acquisition genes were Bvg activated, though the cultures were not iron-depleted, suggesting that Bvg⁺ phase *Bordetella* is primed for iron acquisition prior to actual iron restriction. A gene for an aerolysin/pertussis toxin domain-containing protein (BB3242/BP1251), a potential novel toxin, was Bvg activated in both species.

Three putative adhesin genes, i.e., *fhaS*, *fhaL*, and BB0110, were Bvg activated in RB50 but not GMT-1. The lipid A palmitoyl transferase gene, *pagP*, was Bvg activated in RB50, consistent with prior results (45), but was not regulated in GMT-1. Other RB50-specific Bvg-activated genes included genes encoding protein-folding catalysts, catalase, and a DegP family serine protease (MucD), suggesting that *B. bronchiseptica* may be more resistant to environmental stress in the Bvg⁺




FIG. 2. Validation of *B. bronchiseptica* microarray data by real-time PCR. Ratios of transcript abundance in RB53 (Bvg⁺) versus RB54 (Bvg⁻), obtained by microarray analysis (x axis) or real-time PCR (y axis). Red, Bvg activated; green, Bvg repressed. Selected genes are shown for illustrative purposes.

phase. Of note, two Bvg-activated loci in RB50 were Bvg repressed in GMT-1: *osmB*, encoding a lipoprotein, and a cluster of three hypothetical ORFs.

Consistent with previous results, the *ptx/ptl* locus was strongly upregulated in the Bvg⁺ phase of GMT-1 but not in RB50, in which the promoter is inactive regardless of Bvg phase (2). Other *B. pertussis*-specific Bvg-activated genes included an outer membrane porin gene (BP0267) and a TonB-dependent iron transporter gene (*bfrE*).

Bvg-repressed genes were found almost exclusively in *B. bronchiseptica*. Only 13 genes were Bvg repressed in both species (Fig. 1A), including several genes in the *wlb* locus, which is required for synthesis of the lipopolysaccharide (LPS) trisaccharide. Phase-specific expression of this locus may contribute to the preferential production of O-antigen-containing LPS in the Bvg⁻ phase (45, 58).

Consistent with previous studies (1), the chemotaxis and flagellar machinery was strongly induced in the *B. bronchiseptica* Bvg⁻ phase (see Fig. S1 in the supplemental material). Other *B. bronchiseptica*-specific Bvg-repressed genes of interest are predicted to encode two autotransporters, two iron acquisition proteins, and a 340-kDa protein (BB1186) with multiple hemolysin-type calcium-binding repeats and an associated secretion system. Five genes from the putative capsule biosynthesis locus were upregulated in the Bvg⁻ phase of *B. pertussis* only, implying phase-specific capsule production.

Patterns of BvgAS-regulated gene expression upon environmental modulation. The initial experiments assayed the extreme ends of the Bvg phase spectrum and failed to account fully for genes such as *bipA* that are maximally expressed during other, intermediate phases of Bvg activity. To identify such intermediate-phase genes, expression profiles of Bvgⁱ phase-locked strain derivatives of RB50 and GMT-1 were deter-

mined (see Table S6 in the supplemental material). This approach yielded only a few genes with transcript profiles similar to that of *bipA*, including a gene predicted to encode a probable thiolase (BB4250/BP0422) and, in RB50 only, a predicted phenylacetic acid (*paa*) degradation operon. Because the use of strains locked at only one intermediate state of Bvg activation may not fully reveal all intermediate-phase genes, we pursued an independent and complementary approach.

Cultures can be experimentally held at any point along the BvgAS activation continuum by chemically modulating BvgS activity (e.g., with NA). The pattern of Bvg-regulated gene expression observed in a series of cultures with decreasing concentrations of modulator is recapitulated in the time-dependent pattern of gene expression following a shift from modulating to nonmodulating conditions (reviewed in reference 9). For example, early Bvg-activated genes (e.g., *fhaB*) are expressed immediately after a shift and at intermediate concentrations of modulator, while late Bvg-activated genes (e.g., *ptx*) are expressed at later time points (2 hours or more) after the shift and only at very small amounts of modulator. Here, we use the terms “early” and “late” to describe patterns gleaned from both steady-state modulation and time-dependent shift experiments.

Transcription abundance profiles of RB50 and GMT-1 grown in increasing amounts of NA were determined. Isogenic strain derivatives with a constitutive *bvgS* allele (Bvg^c) were also analyzed to identify genes that respond to NA independently of BvgAS.

(i) *B. bronchiseptica*. In vitro modulation of RB50 revealed remarkably diverse transcript patterns falling into five dominant gene expression classes (Fig. 3). Bvg-repressed, two classes of Bvg-intermediate, and early and late Bvg-activated gene classes were discerned, each with subtle but clear differences in expression patterns. Most Bvg-repressed genes, including motility and chemotaxis loci, were expressed in the presence of 0.8 mM or more NA, but expression of a few genes, including an ABC transporter locus, was activated only at the highest concentration of NA (20 mM).

The earliest Bvg-activated genes, expressed at NA concentrations of up to 0.8 mM, included *bvgAS*, *fhaB* and *fimA* (members of the same operon), and a putative adhesin gene (BB0110). The *cya* operon, *prm*, and other *fim* genes were expressed at up to 0.6 mM NA, while most remaining Bvg-activated genes, including the TTSS locus, were expressed only at NA concentrations of less than or equal to 0.4 mM. These data suggest a trend in which adhesins are expressed early, whereas toxins and the TTSS are expressed later.

The expression pattern of the prototypical intermediate-phase gene *bipA*, peaking at 0.6 and 0.8 mM NA, was virtually unique, with only a few loci showing a similar profile. However, 69 genes, including the *paa* locus and part of the *trp* locus, were maximally expressed at 0.4 to 0.6 mM NA (Fig. 3, Bvgⁱ-a), and another class of 193 genes displayed maximum expression at 0.8 and 1.2 mM NA (Fig. 3, Bvgⁱ-b). Though conceptually similar, the expression peaks for each of these two distinct intermediate regulatory classes occurred at nonoverlapping concentrations of NA. We refer to these Bvg-regulatory phases and their corresponding gene classes as “Bvgⁱ-a” and “Bvgⁱ-b” to distinguish them from the specific point on the Bvg spectrum represented by the Bvgⁱ phase-locked mutation.




FIG. 3. Patterns of Bvg-regulated gene expression in *B. bronchiseptica* RB50. Within each experiment, data are centered and shown from Bvg⁺ (left) to Bvg⁻ (right) to Bvg^c. Rows correspond to array probes, and columns correspond to experiments. +, phase-locked Bvg⁺; i, phase-locked Bvgⁱ; -, phase-locked Bvg⁻. Red, increased transcript abundance; green, decreased transcript abundance; black, no significant change in transcript abundance; gray, no data. NA concentrations (millimolar) are indicated along the bottom. The five major gene expression classes, with some representative loci, and the Bvg-independent NA-induced class are indicated on the right. Purple arrowhead, *bipA*. The set of genes represented by the gray bar on the right passed filtering criteria but showed no discernible pattern.

(ii) *B. pertussis*. In *B. pertussis* GMT-1, the Bvg regulatory continuum was assessed both by steady-state NA modulation and by shifting from the Bvg⁻ to the Bvg⁺ phase following withdrawal of magnesium sulfate from the culture medium. Both treatments resulted in a broad spectrum of expression states that were separable into four dominant gene classes (Fig. 4).

The Bvg⁺ phase gene expression patterns largely paralleled those of RB50, with a few notable differences. As in *B. bronchiseptica*, regulatory (*bvgAS* and *bvgR*) and adhesin (*fhaB* and *prn*) genes were expressed earlier than the TTSS, autotransporter, and toxin (*cya* and *ptx*) genes. Modulation of GMT-1 yielded only a small number of Bvg-repressed genes, expression of which was turned off 90 min after shift or in the presence of 1.2 mM or less NA. These included *wlbD* and the capsule polysaccharide locus.

A few genes were maximally expressed between the Bvg⁺ and Bvg⁻ phases, but only a putative thiolase gene (BP0422) showed a *bipA*-like expression pattern. Expression of 33 genes peaked at 30 min postshift and increased slightly in the range




FIG. 4. Patterns of Bvg-regulated gene expression in *B. pertussis* GMT-1. Data are centered within each experiment. Results obtained with NA modulation and phase-locked strain analysis are shown from Bvg⁺ (left) to Bvg⁻ (right), whereas the phase shift experiment is depicted from Bvg⁻ (left) to Bvg⁺ (right). Rows correspond to array probes, and columns correspond to experiments. +, phase-locked Bvg⁺; i, phase-locked Bvgⁱ; -, phase-locked Bvg⁻. Red, increased transcript abundance; green, decreased transcript abundance; black, no significant change in transcript abundance; gray, no data. NA concentrations (millimolar) and time elapsed after shift (minutes) are indicated along the bottom. The four major gene expression classes, with some representative loci, and the Bvg-independent NA-induced class are indicated on the right. Purple arrowhead, *bipA*. The set of genes represented by the gray bar on the right passed filtering criteria but showed no discernible pattern.

of 0.4 to 1.2 mM NA (Fig. 4, Bvgⁱ-a). The Bvg intermediate gene set in GMT-1 was much less extensive than that in RB50 and, except for *bipA* and BP0422, showed little overlap with the set in RB50.

Regulation of metabolic pathways by BvgAS. In *B. bronchiseptica*, genes related to carbon metabolism and transport functions are dynamically regulated across the Bvg continuum. Bvg⁻ phase transcript profiles suggested increased activity of the tricarboxylic acid (TCA) cycle. Upregulation of C₄-dicarboxylate, tricarboxylate, and branched-chain amino acid transporters might indicate increased concentrations of TCA intermediates and amino acids that can be degraded to acetyl coenzyme A. The rate of conversion of glycine to C₁ units, used to build coenzyme A, may be increased by expression of the glycine cleavage system (*gcvTHP*). Increased expression of arginase (BB0805) may accelerate the urea cycle, yielding fumarate that can be converted to malate by another Bvg-repressed

gene, fumarate hydratase (BB4081). A concordant increase in urea production may explain the observed increase in urease gene expression.

Bvg⁺ phase transcript profiles indicated a shift in carbon source preference: increased abundance of glutamine transporter (*glnHPQ*) and glutamate decarboxylase gene transcripts suggests uptake of glutamine and conversion to glutamate, which may be metabolized to TCA cycle reactants. Lactate and fatty acids appear to be preferred alternative carbon sources, as both L-lactate dehydrogenase and enoyl coenzyme A hydratase genes were upregulated. A shift in nitrogen source preference was also apparent. Expression of *glnHPQ*, together with the upregulation of an ammonia transporter gene (*amtB*) suggest that the organism is optimized for uptake of glutamine and ammonia in the Bvg⁺ phase. Ammonia is a readily available source of nitrogen at the airway epithelial surface (16). In addition to a role in nutrition, *glnHPQ* upregulation might also affect virulence, as *glnQ* mutant group B streptococci are deficient in both epithelial cell binding and infection of an animal model (55).

Regulation by BvgAS of genes encoding respiratory electron transport chain components was evident. In the Bvg⁺ phase, gene transcripts for NADH dehydrogenase, L-lactate dehydrogenase, and a putative cytochrome *c* protein were more abundant, while those for components of the cytochrome *bc*₁ complex, two putative cytochromes, and two ferredoxins were preferentially expressed in the Bvg⁻ phase. In the Bvgⁱ-a phase, genes that encode components of cytochrome *bd* and cytochrome *cbb*₃ were maximally expressed. Both of these terminal oxidases have very high affinity for oxygen and are maximally transcribed under microaerophilic conditions in other bacteria (see e.g., reference 56). Other electron carriers and cytochrome biosynthetic proteins, as well as a cytochrome-containing periplasmic nitrate reductase (*napDABC*) implicated in adaptation to anaerobic environments (51), were also preferentially expressed in the Bvgⁱ-a phase.

Regulation of metabolic and transport functions by BvgAS was much less apparent in *B. pertussis*. The only such components of the *B. pertussis* Bvg⁺ phase transcript pattern shared with *B. bronchiseptica* were the *amtB* ammonium transporter gene and the heme biosynthesis locus. Nutrient transporter operons and cytochrome complex genes were not Bvg regulated in GMT-1. These results suggested that the physiological state of *B. pertussis* is not appreciably regulated by BvgAS and may help to explain the inability of *B. pertussis* to survive in nutrient-limited environments.

Intraspecies variation in BvgAS regulation. Differences in Bvg-regulated gene expression between *Bordetella* species prompted the examination of differential regulation among isolates of the same species. Different regulatory patterns within a species might reflect ongoing microevolution and could cast light upon mechanisms of host adaptation. Diversification of gene expression profiles may also influence pathogenicity, as has been recently suggested for *Mycobacterium tuberculosis* (18).

Bvg-regulated gene expression in RB50 (isolated from a rabbit) was compared to that in phylogenetically distant strains isolated from a human (Bbr77) and from a dog (Bbr81), which were grown in the presence or absence of NA to induce the Bvg⁻ and Bvg⁺ phases, respectively. Comparison of Bvg-reg-

ulated genes revealed a surprising amount of diversity among the three isolates (Fig. 1B; see Fig. S2 in the supplemental material). Of 268 genes that were Bvg activated in at least one strain, only 74 were similarly regulated in all three strains. Several genes that are predicted to encode factors involved in protein folding and ushering (*dsbA*, *dsbG*, and BB3803) and *bfrD*, encoding a putative TonB-dependent iron receptor, were among these genes (Fig. 5A). These also included most known and suspected virulence factors, including seven autotransporters and the TTSS, as well as BB0110, encoding a putative adhesin, and BB3242, encoding a putative toxin. Notable exceptions were *flaS*, *fimX*, and BB0450, which were activated to a lesser extent in Bbr81, and *dnt*, which is missing from the Bbr77 genome and does not appear to be regulated in Bbr81. The strain-specific Bvg-activated genes were rather evenly distributed among most nonessential functional classes (Fig. 5A) and included *risA* (only in RB50) and *bipA* and *ompQ* (only in RB50 and Bbr77).

Of 254 genes that were Bvg repressed in at least one strain, only 73 were similarly regulated in all three strains. These included chemotaxis, motility, LPS biosynthesis, sulfate utilization, and carbon metabolism loci (Fig. 5A). Strain-specific Bvg-repressed genes were distributed over many functional classes, with substantial diversity in expression of genes related to small-molecule degradation and transport (Fig. 5A). Finally, seven genes were Bvg activated in one strain and Bvg repressed in another. In most cases, the gene was not Bvg regulated in the third strain.

In order to investigate *B. pertussis* strain-specific BvgAS regulation, GMT-1, a recent clinical strain, was compared to Tohama I, a strain isolated before widespread pertussis vaccination and subsequently maintained as a laboratory strain. Bvg⁺ and Bvg⁻ phase-locked derivatives of Tohama I were analyzed as described for GMT-1. Many differences between strains were observed, particularly in the Bvg⁻ phase, in which only 23 of the 113 genes repressed in Tohama I were also repressed in GMT-1 (Fig. 1C; see Fig. S4 in the supplemental material). The conserved Bvg-repressed genes mainly belonged to cell envelope, small-molecule degradation, and hypothetical categories (Fig. 5B). Among the strain-specific Bvg-repressed genes were the previously described but functionally uncharacterized *vrg6*, *vrg18*, *vrg24*, and *vrg73* (31), which were Bvg repressed only in Tohama I. Another notable difference between strains was a more extensive and complete Bvg repression of the capsule locus in Tohama I.

Sixty percent of the total *B. pertussis* Bvg-activated genes were similarly regulated in the two *B. pertussis* strains (Fig. 1C). Like in *B. bronchiseptica*, the predominant functional classes among this group were folding and ushering, cell envelope, and transport (Fig. 5B). Most known virulence factors and autotransporters that are present in the *B. pertussis* genome, including the TTSS, were Bvg activated by both strains, as was BB3242, encoding a putative toxin. Interestingly, *fimX*, *flaS*, and *dnt* were Bvg activated only in Tohama I. *fim3* was Bvg activated in GMT-1 but Bvg repressed in Tohama I, as previously described (24).

Mechanisms of differential transcriptional regulation. (i) Comparative analysis of putative transcriptional regulatory sequences. Species- or strain-specific differences in Bvg regulation of a given locus have at least three plausible explanations, with the trivial one being the absence of the gene from




FIG. 5. Functional categorization of ORFs in core and flexible BvgAS regulons. Bvg-regulated genes (red, Bvg activated; green, Bvg repressed) were grouped by functional categories (43, 50). Data are expressed as the percentage that is regulated by BvgAS among all annotated ORFs in each class. (A) *B. bronchiseptica*. ORFs in the core regulon were Bvg regulated by strains RB50, Bbr77, and Bbr81. Those in the flexible regulon were Bvg regulated in either one or two of the three strains. (B) *B. pertussis*. ORFs in the core regulon were Bvg regulated by strains GMT-1 and Tohama I. Those in the flexible regulon were Bvg regulated in only one of the two strains.

one of the genomes. Differential expression of genes present in both genomes can be attributed to either sequence divergence in *cis*-regulatory regions or variation in the levels, activity, or encoding of transcriptional regulatory proteins.

Among 61 loci that were differentially regulated between RB50 and Tohama I, 41 were present in both genomes. Five of the loci that were Bvg activated specifically in RB50 had either an IS481 element or a prophage near the 5' end of the ORF in Tohama I, suggesting that the *cis*-regulatory domains have been disrupted or rearranged in Tohama I (see Table S7 in the supplemental material). At two loci, *fim3* and BB2270/BP1793, large gaps distinguished the *B. bronchiseptica* and *B. pertussis* upstream regions, implicating *cis*-regulatory variation as a likely determinant of differential regulation. Twenty-five of the upstream intergenic regions differed only by single-nucleotide gaps or mismatches, with nucleotide identities ranging from 93.7% to 99.5%. The remaining eight putative promoter regions were identical in the two genomes. For identical upstream regions and, most likely, those with a small number of mismatches, differential regulation can probably be attributed to variation in expression or activity of a transcriptional regulator.

(ii) **Bvg-regulated transcription factors.** Not all Bvg-regulated genes are directly regulated by the binding of BvgA to their promoters (9). Bvg-regulated expression of downstream regulators may lead to fine-tuning of the virulence program, for example, by influencing timing of gene expression or integrating environmental signals.

Genes for the known downstream regulators, BvgR (39) and BtrS (36), and 10 other putative transcriptional regulators were found to be Bvg activated in both *B. bronchiseptica* RB50 and *B. pertussis* Tohama I (see Table S8 in the supplemental material). Genes for 3 putative regulators were Bvg activated specifically in Tohama I, while those for 15 regulators, 8 of which are absent or interrupted in Tohama I, were Bvg activated only in RB50. Eighteen RB50 genes for transcriptional regulators, 11 of which are absent or interrupted in Tohama I, were Bvg repressed, while only 1 was Bvg repressed in Tohama I. As many as 11 transcriptional regulator genes, 7 of which are deleted or disrupted in the *B. pertussis* genome, were maximally expressed in *B. bronchiseptica* in the presence of intermediate NA concentrations, of which only *btr* was regulated in *B. pertussis*. Comparison of the sequences upstream of the

differentially expressed regulatory genes that are intact in both species revealed perfect conservation at four loci and a minimum of 97% identity for the others (see Table S7 in the supplemental material), suggesting that divergence in *cis*-regulatory motifs is not likely to be solely responsible for the observed differences in expression. We propose that the species-specific differences in Bvg-regulated global transcriptional profiles are largely due to the deletion and inactivation in Tohama I of more than two dozen transcriptional regulators that are Bvg regulated in RB50.

Differential expression of transcriptional regulators between strains of the same species was also observed. Genes for seven putative regulatory proteins that were Bvg activated in either Tohama I or GMT-1 were differentially regulated between the two isolates (see Table S8 in the supplemental material). Among *B. bronchiseptica* isolates, 22 likely transcriptional regulatory protein genes that were Bvg activated, and 13 that were Bvg repressed, were differentially regulated. Thus, transcriptional regulation of downstream regulators by BvgAS can vary dramatically from strain to strain, which may profoundly affect global transcriptional profiles and the phenotypes conferred.

(iii) Identification of putative regulatory motifs. Although the binding of BvgA to a few virulence factor gene promoters has been well characterized, little is known about regulatory control of most Bvg-regulated genes. To identify putative *cis*-regulatory sequences, the upstream regions of Bvg-regulated transcription units were searched for common motifs by using the pattern detection algorithm MEME (3). Motifs that were significantly enriched among an expression class were identified by comparing the distributions of motif scores in the upstream regions of Bvg-regulated versus Bvg-unregulated genes.

Some regions upstream of Bvg-activated and Bvg-repressed genes were enriched for motifs reminiscent of the traditional BvgA-binding consensus site (TTT[C/G]NTA) and suggestive of an inverted repeat. A weighted statistical model constructed from high-scoring putative BvgA half-sites identified the experimentally confirmed high-affinity BvgA-binding sites in the promoters of *bvgA*, *flaB*, *cyaA*, and *bipA* (4, 15, 27, 28) (see Table S9 in the supplemental material). These sites consisted of a high-scoring heptad adjacent to a lower scoring inverted heptad (Fig. 6A). A putative binding motif was found upstream of *prn* and 11 other Bvg-activated RB50 genes and of 6 other Bvg-activated Tohama I genes at an average distance of 168 nt from the predicted start codon. The majority of the putative BvgA-binding motifs identified by this approach did not contain substitutions in their high-scoring heptads that have been shown to abolish *in vivo* activity of the *flaB* promoter (6). However, several of the motifs did harbor such substitutions (e.g., A, T, or G instead of C in position 4), suggesting that these motifs may not actually represent functional BvgA-binding sites (see Table S9 in the supplemental material).

In the upstream regions of genes that were Bvg activated at early time points, the half-sites of the predicted BvgA-binding site were adjacent, while upstream of late Bvg-activated genes, the half-sites tended to be separated by one or two bases, suggesting that extra bases between the half-sites may reduce affinity for BvgA dimers and lead to delayed transcriptional activation. The BvgA motif model also identified the high-affinity binding site in the *bipA* promoter and putative sites upstream of nine other RB50 Bvg¹-a and Bvg¹-b phase genes.




FIG. 6. Putative *cis*-regulatory motifs. Multiple alignments are represented as sequence logos. *x* axis, nucleotide position within motif; *y* axis, bit score. Arrows indicate putative half-sites. (A) BvgA-binding motif from regions upstream of Bvg-activated genes. Dashed line, variable-length (0- to 2-nt) spacer between half-sites. (B) Fim box. Solid lines, box 1 and box 2; dashed line, beginning of poly(C) tract. (C and D) FNR box (C) and palindromic motif (D) from regions upstream of Bvg¹-b genes.

Putative BvgA-binding sites were also found upstream of Bvg-repressed genes (see Table S9 in the supplemental material). However, sites from Bvg⁺ and Bvg⁻ phase genes were indistinguishable (data not shown) and distances to the predicted start codons were similar, suggesting that the putative BvgA-binding site position relative to the core promoter may not determine activation versus repression. We speculate that BvgA may act as a transcriptional repressor, even when bound far upstream of the core promoter, implying a different mechanism than the RNA polymerase interference proposed for repression of *bipA* (15, 62).

Surprisingly, only 11% of the Bvg⁺ and Bvg⁻ phase gene upstream regions possessed discernible high-affinity BvgA-binding sites as defined by the motif model, suggesting that the actual BvgA-binding motif may be highly degenerate, an interpretation supported by the failure of this model to identify a BvgA-binding site in the *bvgR* and *ptx* promoters, both of which bind BvgA (5, 38). Alternatively, expression of many Bvg-regulated genes may be governed by downstream transcriptional regulators.

A motif corresponding to the Fim box (48) (Fig. 6B) was found upstream of all fimbrial major subunit genes except *fimA*, as well as four other RB50 Bvg-activated genes (*flaS*, *tcfA*, the glutamate decarboxylase gene, and an autotransporter gene) and two Tohama I Bvg-activated genes (*vag8* and *bapC*), suggesting that these confirmed and likely virulence factors may be coregulated with fimbriae. Although *fim3* is Bvg repressed in Tohama I, the promoter has an intact Fim box. This motif was also found upstream of three RB50 Bvg-repressed genes as well as the Tohama I Bvg-repressed capsular polysaccharide locus promoter, suggesting that its cognate binding factor may promote transcriptional repression as well as activation.

Among the 25 RB50 Bvg¹-a phase operons, a single motif was present in seven upstream regions, including those of several respiratory complex loci (Fig. 6C). This highly conserved, palin-

dromic motif corresponds to the FNR box, the binding site for Fnr, a highly conserved transcriptional regulator that controls respiration pathways under low-oxygen conditions in *Escherichia coli* and a number of other bacterial species (52). The *Bordetella* homologue of Fnr, Btr, was coexpressed with its putative target genes, suggesting that Btr may activate these genes.

Among the promoters of RB50 loci maximally expressed at 0.8 to 1.2 mM NA, three palindromic motifs were identified, together accounting for 15% of the genes in this class. One of these motifs (Fig. 6D) has the length and spacing typically observed for LysR family transcription factor-binding sites, suggesting that it might be the recognition site for one of the several LysR family proteins maximally expressed in this phase.

Overall, putative regulatory motifs that were significantly overrepresented among the Bvg-regulated gene class were identified upstream of only one-third of the Bvg-regulated genes. This relatively low percentage of Bvg-regulated loci may reflect degeneracy of recognition sites, cooperativity between multiple poorly conserved sites, or the existence of many small subregulons, each with a unique regulator. Identifying the *cis*-regulatory sequences of the remaining loci will require further exploration, and validation of the sites described here will require direct experimentation.

DISCUSSION

Differentiation of Bvg-regulated gene expression. Comparative global expression analysis revealed unexpected complexity of the *Bordetella* BvgAS regulon and insights into possible evolutionary paths for virulence regulation among strains and species of an important group of bacterial pathogens. In particular, *B. bronchiseptica*, a pathogen and persistent commensal in a broad set of animal species, displayed a wide variety of gene expression profiles *in vitro*. These profiles may reflect spatially and/or temporally defined patterns during the infectious cycle. The spatial model proposes that colonization of different airway niches and the process of transmission require overlapping yet distinct sets of gene products, the expression of which is regulated by BvgAS in response to environmental conditions characteristic of those anatomic locations. Alternatively, or in addition, BvgAS may regulate a gene expression program in a temporally defined manner, facilitating the establishment of infection (49). The steady-state modulation and phase shift experiments described in this study can be considered *in vitro* counterparts of the spatial and temporal models, respectively. Although these models are not necessarily mutually exclusive, expression of metabolic genes, especially respiratory chain components, suggests that the phases are tuned to different environmental niches, favoring spatially defined regulation.

Patterns of Bvg-activated gene expression in *B. bronchiseptica* and *B. pertussis* were similar, emphasizing that the Bvg⁺ phase serves similar functions in their respective life cycles. The differentially expressed Bvg-activated genes identified here are candidate determinants of *Bordetella* host specificity. For example, *B. bronchiseptica*-specific expression of the putative adhesin BB0110 and several *fim* genes could contribute to its wider host range compared to *B. pertussis*.

In contrast, the Bvg⁻ phases of the two species were remarkably different. In *B. bronchiseptica*, the multitude of Bvg-

repressed metabolic, transport, motility, and chemotaxis loci suggests that this phase is optimized for nutrient scavenging and survival *ex vivo*. However, these gene classes have been shown to be important for *in vivo* survival in other systems (see, e.g., references 14 and 26), so a role for the Bvg⁻ phase within the host cannot be ruled out. The number and diversity of *B. pertussis* Bvg⁻ phase genes were limited, reflecting either a different function for the Bvg⁻ phase or the loss of expression, subsequent to host restriction, of loci that facilitate survival *ex vivo*. The near-complete discordance of Bvg⁻ phase expression patterns of *B. pertussis* strains GMT-1 and Tohama I supports the latter scenario, as lack of selective pressure is likely to result in random loss and heterogeneity of Bvg⁻ phase factors. These data support the suggestion that the *B. pertussis* Bvg⁻ phase is an evolutionary remnant (9, 40). Of note, *B. bronchiseptica* strains also differed in Bvg⁻ phase expression patterns, but to a lesser extent than *B. pertussis*, possibly reflecting a preference of these strains for different *ex vivo* niches or redundancy in the Bvg-repressed gene repertoire or, alternatively, suggesting partial random degradation of the Bvg⁻ phase in this species as well.

This is the most extensive comparative analysis of the *Bordetella* transitional phases along the Bvg regulatory continuum. Prior to this study, with the exception of a few genes (see, e.g., references 15, 46, and 49), expression patterns between the Bvg⁺ and Bvg⁻ phases had not been determined. Only a single intermediate-phase gene, *bipA*, had been identified, and the Bvgⁱ phases of *B. pertussis* and *B. bronchiseptica* were thought to be fairly similar. In our study, features of the intermediate Bvg phases were among the more unexpected findings. In *B. bronchiseptica* RB50 there are at least two distinct gene expression states between the Bvg⁺ and Bvg⁻ poles, comprising 262 genes. These genes may facilitate survival in different environmental niches through activation of specific metabolic and transport pathways. An even higher-resolution examination of the Bvg regulation spectrum may reveal further distinct phenotypic phases. The ability of BvgAS to transduce environmental signals into a series of discrete gene expression states could also be a feature of other regulatory systems. However, because gene regulation studies have historically focused on the endpoints of the spectrum, this has, as yet, remained unrecognized. We propose that examination of transcriptional profiles of other regulatory systems at intermediate levels of environmental signals may reveal regulatory spectra analogous to that described here for BvgAS.

Because intermediate-phase gene expression patterns were found to differ significantly between the two species, these phases may provide species-specific functions in addition to the putative roles in aerosol transmission and biofilm formation (25, 60). Preferential expression in the Bvg^{1-a} phase of *B. bronchiseptica* of genes for respiratory terminal oxidases with high oxygen affinity suggests that this phase may be optimized for survival in microaerophilic conditions, which may be encountered at the airway epithelium due to the accumulation of mucus and debris. *B. pertussis* intermediate-phase expression patterns did not group into discrete classes as in *B. bronchiseptica*, nor did they suggest an obvious physiological role, suggesting that this phase may be an evolutionary remnant in *B. pertussis*.

Exploring the flexible regulon. This study joins a growing number of reports (see, e.g., references 18, 19, and 61) in demonstrating that global transcript or protein profiles among strains of the same species can be highly variable. Consequently, gene expression data from a single strain may not reflect the prevailing expression profile of that species. For example, the most frequently studied *B. pertussis* Bvg-repressed genes were identified in the *B. pertussis* type strain 18-323 (31), yet the present data did not reveal Bvg repression of any of these loci in GMT-1, raising the question of whether Bvg-regulated expression of these genes is a feature of modern clinical isolates.

Among strains of a single microbial species, genomic content can vary substantially (32). Genes that are present in all isolates (i.e., the “core genome”) are assumed to be phylogenetically conserved, while those that are variably present (i.e., the “flexible genome”) are proposed to be horizontally acquired or differentially lost within the species. The components of the flexible genome are thought to confer differences in phenotypes such as virulence and host range. We favor an analogous distinction for the description of gene regulation patterns found in related strains in response to a stimulus and propose that a global gene expression profile comprises a “core regulon” that is shared among all strains and a “flexible regulon” that varies between strains. Regulated expression of each gene in the core regulon is presumed to be required by every isolate of a species. For a pathogen grown under conditions that promote virulence, the core regulon includes factors that are required for efficient infection and transmission. Therefore, components of the core regulon are the best candidate vaccine or therapeutic targets. On the other hand, regulated expression of the genes in the flexible regulon is not required by every strain, and variation in the expression of these genes is tolerated within the population. In a pathogen population, the flexible regulon could include determinants of host specificity, thus facilitating its spread into new hosts or, conversely, its restriction to a single host. More generally, the flexible regulon could reflect adaptation to specific habitats by subpopulations. We believe that differentially expressed loci are an informative class of Bvg-regulated genes and may prove critical in our understanding of evolution and diversification of host range specificity between and within *Bordetella* species.

One important determinant of the flexible regulon is the collection of downstream transcriptional regulators that are themselves regulated, directly or indirectly, by the core top-level regulators. Because each transcription factor may be capable of modifying the expression patterns of many individual loci, a single mutation that changes the concentration or activity of a regulator can have widespread effects on the global expression pattern. Indeed, we observed differential regulation of many putative transcriptional regulators, both within and between *Bordetella* species. This variability in regulatory protein repertoires could represent an efficient and powerful way to generate phenotypic diversity during evolution and may be one of the predominant mechanisms of differential gene expression in the bordetellae.

ACKNOWLEDGMENTS

We thank Mary Brinig and Mari Nakamura for microarray production and critical review of the manuscript, Sin-Yee Liew for technical assistance, Peggy Cotter (University of California, Santa Barbara) for

strains, and Peter Karp (SRI International) for providing *Bordetella* pathway genome databases before publication.

C.A.C. was supported by Research Training Fellowships from the American Lung Association and ALA-California. H.J.B. was funded (in part) by a TALENT fellowship from The Netherlands Organization for Scientific Research (NWO). J.F.M. was supported by NIH/NIAID grants AI38417 and AI061598. D.A.R. was supported by NIH/NIAID grants AI54970 and AI057188.

REFERENCES

- Akerley, B. J., P. A. Cotter, and J. F. Miller. 1995. Ectopic expression of the flagellar regulon alters development of the *Bordetella*-host interaction. *Cell* **80**:611–620.
- Arico, B., and R. Rappuoli. 1987. *Bordetella parapertussis* and *Bordetella bronchiseptica* contain transcriptionally silent pertussis toxin genes. *J. Bacteriol.* **169**:2847–2853.
- Bailey, T. L., and C. Elkan. 1994. Fitting a mixture model by expectation maximization to discover motifs in biopolymers, p. 28–36. *In* Proceedings of the Second International Conference on Intelligent Systems for Molecular Biology. AAAI Press, Menlo Park, Calif.
- Boucher, P. E., K. Murakami, A. Ishihama, and S. Stibitz. 1997. Nature of DNA binding and RNA polymerase interaction of the *Bordetella pertussis* BvgA transcriptional activator at the *fla* promoter. *J. Bacteriol.* **179**:1755–1763.
- Boucher, P. E., and S. Stibitz. 1995. Synergistic binding of RNA polymerase and BvgA phosphate to the pertussis toxin promoter of *Bordetella pertussis*. *J. Bacteriol.* **177**:6486–6491.
- Boucher, P. E., M. S. Yang, and S. Stibitz. 2001. Mutational analysis of the high-affinity BvgA binding site in the *fla* promoter of *Bordetella pertussis*. *Mol. Microbiol.* **40**:991–999.
- Centers for Disease Control and Prevention. 2002. Pertussis—United States, 1997–2000. *Morb. Mortal. Wkly. Rep.* **51**:73–76.
- Cotter, P. A., and A. M. Jones. 2003. Phosphorelay control of virulence gene expression in *Bordetella*. *Trends Microbiol.* **11**:367–373.
- Cotter, P. A., and J. F. Miller. 2001. *Bordetella*, p. 620–674. *In* E. A. Groisman (ed.), Principles of bacterial pathogenesis. Academic Press, San Diego, Calif.
- Cotter, P. A., and J. F. Miller. 1994. BvgAS-mediated signal transduction: analysis of phase-locked regulatory mutants of *Bordetella bronchiseptica* in a rabbit model. *Infect. Immun.* **62**:3381–3390.
- Cotter, P. A., and J. F. Miller. 1997. A mutation in the *Bordetella bronchiseptica* *bvgS* gene results in reduced virulence and increased resistance to starvation, and identifies a new class of Bvg-regulated antigens. *Mol. Microbiol.* **24**:671–685.
- Crooks, G. E., G. Hon, J. M. Chandonia, and S. E. Brenner. 2004. WebLogo: a sequence logo generator. *Genome Res.* **14**:1188–1190.
- Cummings, C. A., M. M. Brinig, P. W. Lepp, S. van de Pas, and D. A. Relman. 2004. *Bordetella* species are distinguished by patterns of substantial gene loss and host adaptation. *J. Bacteriol.* **186**:1484–1492.
- Davidson, A. L., and J. Chen. 2004. ATP-binding cassette transporters in bacteria. *Annu. Rev. Biochem.* **73**:241–268.
- Deora, R., H. J. Bootsma, J. F. Miller, and P. A. Cotter. 2001. Diversity in the *Bordetella* virulence regulon: transcriptional control of a Bvg-intermediate phase gene. *Mol. Microbiol.* **40**:669–683.
- Dwyer, T. M. 2004. Sampling airway surface liquid: non-volatiles in the exhaled breath condensate. *Lung* **182**:241–250.
- Fuchslocher, B., L. L. Millar, and P. A. Cotter. 2003. Comparison of *bipA* alleles within and across *Bordetella* species. *Infect. Immun.* **71**:3043–3052.
- Gao, Q., K. E. Kripke, A. J. Saldanha, W. Yan, S. Holmes, and P. M. Small. 2005. Gene expression diversity among *Mycobacterium tuberculosis* clinical isolates. *Microbiology* **151**:5–14.
- Gaynor, E. C., S. Cawthraw, G. Manning, J. K. MacKichan, S. Falkow, and D. G. Newell. 2004. The genome-sequenced variant of *Campylobacter jejuni* NCTC 11168 and the original clonal clinical isolate differ markedly in colonization, gene expression, and virulence-associated phenotypes. *J. Bacteriol.* **186**:503–517.
- Gerlach, G., F. von Wintzingerode, B. Middendorf, and R. Gross. 2001. Evolutionary trends in the genus *Bordetella*. *Microbes Infect.* **3**:61–72.
- Goodnow, R. A. 1980. Biology of *Bordetella bronchiseptica*. *Microbiol. Rev.* **44**:722–738.
- Heininger, U., K. Stehr, S. Schmitt-Grohe, C. Lorenz, R. Rost, P. D. Christenson, M. Uberall, and J. D. Cherry. 1994. Clinical characteristics of illness caused by *Bordetella parapertussis* compared with illness caused by *Bordetella pertussis*. *Pediatr. Infect. Dis. J.* **13**:306–309.
- Herrero, J., A. Valencia, and J. Dopazo. 2001. A hierarchical unsupervised growing neural network for clustering gene expression patterns. *Bioinformatics* **17**:126–136.
- Hot, D., R. Antoine, G. Renaud-Mongenien, V. Caro, B. Hennuy, E. Levillain, L. Huot, G. Wittmann, D. Poncet, F. Jacob-Dubuisson, C. Guyard, F. Rimlinger, L. Aujame, E. Godfroid, N. Guiso, M. J. Quentin-Millet, Y. Lemoine, and C. Locht. 2003. Differential modulation of *Bordetella pertussis* virulence genes as evidenced by DNA microarray analysis. *Mol. Genet. Genomics* **269**:475–486.

25. Irie, Y., S. Mattoo, and M. H. Yuk. 2004. The Bvg virulence control system regulates biofilm formation in *Bordetella bronchiseptica*. *J. Bacteriol.* **186**:5692–5698.
26. Josenhans, C., and S. Suerbaum. 2002. The role of motility as a virulence factor in bacteria. *Int. J. Med. Microbiol.* **291**:605–614.
27. Karimova, G., J. Bellalou, and A. Ullmann. 1996. Phosphorylation-dependent binding of BvgA to the upstream region of the *cydA* gene of *Bordetella pertussis*. *Mol. Microbiol.* **20**:489–496.
28. Karimova, G., and A. Ullmann. 1997. Characterization of DNA binding sites for the BvgA protein of *Bordetella pertussis*. *J. Bacteriol.* **179**:3790–3792.
29. Karp, P. D., S. Paley, and P. Romero. 2002. The Pathway Tools software. *Bioinformatics* **18**(Suppl. 1):S225–S232.
30. Kasuga, T., Y. Nakase, K. Ukishima, and K. Takatsu. 1954. Studies on *Haemophilus pertussis*. V. Relation between the phase of bacilli and the progress of the whooping-cough. *Kitasato Arch. Exp. Med.* **27**:57–62.
31. Knapp, S., and J. J. Mekalanos. 1988. Two *trans*-acting regulatory genes (*vir* and *mod*) control antigenic modulation in *Bordetella pertussis*. *J. Bacteriol.* **170**:5059–5066.
32. Lan, R., and P. R. Reeves. 2000. Intraspecies variation in bacterial genomes: the need for a species genome concept. *Trends Microbiol.* **8**:396–401.
33. Livak, K. J., and T. D. Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the $2^{-\Delta\Delta C_T}$ method. *Methods* **25**:402–408.
34. Martínez de Tejada, G., P. A. Cotter, U. Heininger, A. Camilli, B. J. Akerley, J. J. Mekalanos, and J. F. Miller. 1998. Neither the Bvg⁻ phase nor the *vrg6* locus of *Bordetella pertussis* is required for respiratory infection in mice. *Infect. Immun.* **66**:2762–2768.
35. Martínez de Tejada, G., J. F. Miller, and P. A. Cotter. 1996. Comparative analysis of the virulence control systems of *Bordetella pertussis* and *Bordetella bronchiseptica*. *Mol. Microbiol.* **22**:895–908.
36. Mattoo, S., M. H. Yuk, L. L. Huang, and J. F. Miller. 2004. Regulation of type III secretion in *Bordetella*. *Mol. Microbiol.* **52**:1201–1214.
37. Melton, A. R., and A. A. Weiss. 1989. Environmental regulation of expression of virulence determinants in *Bordetella pertussis*. *J. Bacteriol.* **171**:6206–6212.
38. Merkel, T. J., P. E. Boucher, S. Stibitz, and V. K. Grippo. 2003. Analysis of *bvgR* expression in *Bordetella pertussis*. *J. Bacteriol.* **185**:6902–6912.
39. Merkel, T. J., and S. Stibitz. 1995. Identification of a locus required for the regulation of *bvg*-repressed genes in *Bordetella pertussis*. *J. Bacteriol.* **177**:2727–2736.
40. Merkel, T. J., S. Stibitz, J. M. Keith, M. Leef, and R. Shahin. 1998. Contribution of regulation by the *bvg* locus to respiratory infection of mice by *Bordetella pertussis*. *Infect. Immun.* **66**:4367–4373.
41. Miller, J. F., S. A. Johnson, W. J. Black, D. T. Beattie, J. J. Mekalanos, and S. Falkow. 1992. Constitutive sensory transduction mutations in the *Bordetella pertussis* *bvgS* gene. *J. Bacteriol.* **174**:970–979.
42. Mooi, F. R., I. H. van Loo, and A. J. King. 2001. Adaptation of *Bordetella pertussis* to vaccination: a cause for its reemergence? *Emerg. Infect. Dis.* **7**:526–528.
43. Parkhill, J., M. Sebahia, A. Preston, L. D. Murphy, N. Thomson, D. E. Harris, M. T. G. Holden, C. R. Churcher, S. D. Bentley, K. L. Mungall, A. M. Cerdeño-Tárraga, L. Temple, K. James, B. Harris, M. A. Quail, M. Achtman, R. Atkin, S. Baker, D. Basham, N. Bason, I. Cherevach, T. Chillingworth, M. Collins, A. Cronin, P. Davis, J. Doggett, T. Feltwell, A. Goble, N. Hamlin, H. Hauser, S. Holroyd, K. Jagels, S. Leather, S. Moule, H. Norberczak, S. O'Neil, D. Ormond, C. Price, E. Rabinowitsch, S. Rutter, M. Sanders, D. Saunders, K. Seeger, S. Sharp, M. Simmonds, J. Skelton, R. Squares, R. Squares, K. Stevens, L. Unwin, S. Whitehead, B. G. Barrell, and D. J. Maskell. 2003. Comparative analysis of the genome sequences of *Bordetella pertussis*, *Bordetella parapertussis* and *Bordetella bronchiseptica*. *Nat. Genet.* **35**:32–40.
44. Porter, J. F., R. Parton, and A. C. Wardlaw. 1991. Growth and survival of *Bordetella bronchiseptica* in natural waters and in buffered saline without added nutrients. *Appl. Environ. Microbiol.* **57**:1202–1206.
45. Preston, A., E. Maxim, E. Toland, E. J. Pishko, E. T. Harvill, M. Caroff, and D. J. Maskell. 2003. *Bordetella bronchiseptica* PagP is a Bvg-regulated lipid A palmitoyl transferase that is required for persistent colonization of the mouse respiratory tract. *Mol. Microbiol.* **48**:725–736.
46. Prugnola, A., B. Arico, R. Manetti, R. Rappuoli, and V. Scarlato. 1995. Response of the *bvg* regulon of *Bordetella pertussis* to different temperatures and short-term temperature shifts. *Microbiology* **141**:2529–2534.
47. Ren, Q., K. H. Kang, and I. T. Paulsen. 2004. TransportDB: a relational database of cellular membrane transport systems. *Nucleic Acids Res.* **32**:D284–D288.
48. Riboli, B., P. Pedroni, A. Cuzzoni, G. Grandi, and F. de Ferra. 1991. Expression of *Bordetella pertussis* fimbrial (*fim*) genes in *Bordetella bronchiseptica*: *fimX* is expressed at a low level and *vir*-regulated. *Microb. Pathog.* **10**:393–403.
49. Scarlato, V., B. Arico, A. Prugnola, and R. Rappuoli. 1991. Sequential activation and environmental regulation of virulence genes in *Bordetella pertussis*. *EMBO J.* **10**:3971–3975.
50. Serres, M. H., and M. Riley. 2000. MultiFun, a multifunctional classification scheme for *Escherichia coli* K-12 gene products. *Microb. Comp. Genomics* **5**:205–222.
51. Siddiqui, R. A., U. Warnecke-Eberz, A. Hengsberger, B. Schneider, S. Kostka, and B. Friedrich. 1993. Structure and function of a periplasmic nitrate reductase in *Alcaligenes eutrophus* H16. *J. Bacteriol.* **175**:5867–5876.
52. Spiro, S. 1994. The FNR family of transcriptional regulators. *Antonie Leeuwenhoek* **66**:23–36.
53. Stockbauer, K. E., B. Fuchslocher, J. F. Miller, and P. A. Cotter. 2001. Identification and characterization of BipA, a *Bordetella* Bvg-intermediate phase protein. *Mol. Microbiol.* **39**:65–78.
54. Talaat, A. M., S. T. Howard, W. ten Hale, R. Lyons, H. Garner, and S. A. Johnston. 2002. Genomic DNA standards for gene expression profiling in *Mycobacterium tuberculosis*. *Nucleic Acids Res.* **30**:e104.
55. Tamura, G. S., A. Nittayajarn, and D. L. Schoentag. 2002. A glutamine transport gene, *glnQ*, is required for fibronectin adherence and virulence of group B streptococci. *Infect. Immun.* **70**:2877–2885.
56. Tseng, C. P., J. Albrecht, and R. P. Gunsalus. 1996. Effect of microaerophilic cell growth conditions on expression of the aerobic (*cyoABCDE* and *cydAB*) and anaerobic (*narGHJI*, *frdABCD*, and *dmsABC*) respiratory pathway genes in *Escherichia coli*. *J. Bacteriol.* **178**:1094–1098.
57. Tusher, V. G., R. Tibshirani, and G. Chu. 2001. Significance analysis of microarrays applied to the ionizing radiation response. *Proc. Natl. Acad. Sci. USA* **98**:5116–5121.
58. van den Akker, W. M. 1998. Lipopolysaccharide expression within the genus *Bordetella*: influence of temperature and phase variation. *Microbiology* **144**:1527–1535.
59. van der Zee, A., F. Mooi, J. Van Embden, and J. Musser. 1997. Molecular evolution and host adaptation of *Bordetella* spp.: phylogenetic analysis using multilocus enzyme electrophoresis and typing with three insertion sequences. *J. Bacteriol.* **179**:6609–6617.
60. Vergara-Irigaray, N., A. Chavarri-Martinez, J. Rodriguez-Cuesta, J. F. Miller, P. A. Cotter, and G. Martínez de Tejada. 2005. Evaluation of the role of the Bvg intermediate phase in *Bordetella pertussis* during experimental respiratory infection. *Infect. Immun.* **73**:748–760.
61. Wehmhoner, D., S. Haussler, B. Tummeler, L. Jansch, F. Bredenbruch, J. Wehland, and I. Steinmetz. 2003. Inter- and intracellular diversity of the *Pseudomonas aeruginosa* proteome manifests within the secretome. *J. Bacteriol.* **185**:5807–5814.
62. Williams, C. L., P. E. Boucher, S. Stibitz, and P. A. Cotter. 2005. BvgA functions as both an activator and a repressor to control Bvg¹ phase expression of *bipA* in *Bordetella pertussis*. *Mol. Microbiol.* **56**:175–188.
63. Yeh, S. H. 2003. Pertussis: persistent pathogen, imperfect vaccines. *Expert Rev. Vaccines* **2**:113–127.